GrayBug Secures Worldwide Rights to Develop Proprietary Ophthalmic Drug Delivery Platforms


GrayBug raises $1mm from investors and is awarded a $200k grant to support research

Baltimore, MD – April 11, 2012 – GrayBug LLC announced today they have raised over $1 million in equity from investors and have successfully obtained the worldwide right to new technologies invented by GrayBug LLC co-founders Justin Hanes, Peter Campochiaro, and Peter McDonnell through a licensing deal with the John Hopkins University.

GrayBug was also awarded a $200k grant from The Maryland Biotechnology Center through their Biotech Development Program to support development of the company’s lead product targeting Age Related Macular Degeneration (AMD).

GrayBug is a biotechnology company that is developing proprietary controlled release technologies for pharmaceutical indications. The company’s lead product is a polymer-drug biomolecular conjugate for the treatment of neovascular diseases of the eye. GrayBug’s proprietary platform technology allows sustained drug delivery into various compartments of the eye while minimizing inflammation common with current controlled release technologies applied to the eye.

Related News

Press release

Graybug Vision CEO to Participate in OIS@ASRS Conference

– Company to Discuss Upcoming Phase 1/2 Study of Twice Per Year Treatment for AMD – Redwood City, CA – August 8, 2017 – Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially Read more…

Press release

Valerie Smith Joins Graybug Vision as VP, Global Clinical Development Operations

Redwood City, CA – May 8, 2017 – Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially transformative therapies for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, today announced that Read more…

Press release

Graybug Vision’s Potential Once-Per-Year AMD Treatment Data Presented at ARVO 2017

– Company Developing Injectable Products for Treating Glaucoma and AMD – Redwood City, CA – May 8, 2017 – Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially transformative therapies for ocular diseases Read more…